You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

CLINICAL TRIALS PROFILE FOR LUMIFY


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Lumify

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03782701 ↗ The Effect of Lumify™ Eyedrops on Eyelid Position Completed University of Miami Phase 4 2019-06-18 The purpose of the research is to see if Lumify™ has an effect on eyelid position.
NCT03782701 ↗ The Effect of Lumify™ Eyedrops on Eyelid Position Completed Wendy Lee Phase 4 2019-06-18 The purpose of the research is to see if Lumify™ has an effect on eyelid position.
NCT04007276 ↗ The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Not yet recruiting Tulane University Phase 4 2025-11-10 Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.
NCT04024891 ↗ Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis Completed Ocuphire Pharma, Inc. Phase 2 2019-08-13 The objectives of this study are: - To evaluate the efficacy of Nyxol (phentolamine mesylate ophthalmic solution 1%) to expedite the reversal of pharmacologic mydriasis - To evaluate the safety of Nyxol - To evaluate the effect of Lumify® to suppress conjunctival hyperemia (redness) potentially associated with administration of Nyxol
NCT04683159 ↗ Brimonidine Tartrate for Pterygium Surgery Not yet recruiting Uptown Eye Specialists N/A 2021-02-01 Pterygium excision and conjunctival autograft surgery is commonly done to treat pterygiums. Excessive bleeding during the procedure creates a challenging operating field, prolongs surgery time, and prolongs healing. Brimonidine tartrate has a vasoconstrictive effect, which helps to reduce the amount of blood flow and hyperemia to the eye. Preoperative use of brimonidine has been shown to decrease subconjunctival hemorrhage during procedures such as cataract surgery, laser assisted in situ keratomileusis, strabismus surgery, and intravitreal injections. The focus of this study is to assess the effect of preoperative application of brimonidine tartrate 0.15% (Alphagan) and 0.025% (Lumify) on reducing hemorrhage during pterygium excision and conjunctival autograft surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lumify

Condition Name

Condition Name for Lumify
Intervention Trials
Ocular Redness 1
Dilation 1
Pterygium 1
Droopy Eyelid 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lumify
Intervention Trials
Blepharoptosis 3
Pterygium 1
Hemorrhage 1
Mydriasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lumify

Trials by Country

Trials by Country for Lumify
Location Trials
United States 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lumify
Location Trials
Kentucky 3
Utah 1
Tennessee 1
North Carolina 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lumify

Clinical Trial Phase

Clinical Trial Phase for Lumify
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lumify
Clinical Trial Phase Trials
Not yet recruiting 3
Completed 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lumify

Sponsor Name

Sponsor Name for Lumify
Sponsor Trials
Wendy Lee 1
Tulane University 1
Ocuphire Pharma, Inc. 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lumify
Sponsor Trials
Other 5
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

LUMIFY: A Comprehensive Overview of Clinical Trials, Market Analysis, and Projections

Introduction to LUMIFY

LUMIFY, developed by Bausch + Lomb, is the first and only over-the-counter (OTC) eye drop formulated with low-dose brimonidine tartrate (0.025%) to treat ocular redness due to minor eye irritations. Since its FDA approval in 2017, LUMIFY has garnered significant attention and accolades for its efficacy and safety profile.

Clinical Trials and Studies

Current and Ongoing Trials

One notable ongoing trial involves testing LUMIFY in glaucoma patients who are already using brimonidine eye drops. This phase 4 trial aims to evaluate the effects of LUMIFY on ocular redness, intraocular pressure (IOP), and eyelid position in these patients. The study compares LUMIFY (brimonidine tartrate ophthalmic solution 0.025%) against a saline solution to assess its efficacy and safety in this specific patient population[4].

Key Objectives and Outcomes

The primary objectives of this trial include measuring intraocular pressure and ocular redness. Secondary objectives focus on eye discomfort and palpebral fissure height. The trial is designed to provide further data on the use of LUMIFY in patients with glaucoma, who often experience red eyes as a side effect of their current treatment.

Previous Clinical Trials and Approval

LUMIFY has already demonstrated its efficacy in clinical trials prior to its FDA approval. These trials showed significant reduction in ocular redness as early as one minute after application, with the effects lasting up to eight hours[3].

Market Analysis

Market Performance and Recognition

Since its launch, LUMIFY has achieved remarkable market success. It has been recognized by Nielsen's BASES as one of the 2020 U.S. BASES Top 25 Breakthrough Innovations in the "Superstar" category for its exceptional sales and growth. LUMIFY holds the No. 1 dollar share among redness relievers, with a 40% market share in the latest 52 weeks. It is also the No. 1 eye doctor-recommended brand, with approximately 79% of doctor recommendations[5].

Consumer Impact and Cultural Integration

LUMIFY has become ingrained in popular culture through an integrated consumer campaign highlighting its ability to reduce redness and make eyes appear whiter, brighter, and more radiant. This campaign has brought in over a million first-time users into the eye redness reliever category, significantly driving category growth[5].

Market Projections

Current Market Position

LUMIFY's dominance in the eye redness reliever market is expected to continue, given its strong brand recognition and doctor recommendations. Its unique formulation with low-dose brimonidine tartrate reduces the risk of rebound redness and loss of efficacy over time, making it a preferred choice among consumers and healthcare professionals alike[5].

Future Competition and Generic Entries

Lupin Limited has recently received tentative approval from the FDA for its generic version of LUMIFY. However, this generic version cannot be marketed in the United States until all patent or exclusivity issues related to the original LUMIFY product are resolved. This delay could take several years, allowing LUMIFY to maintain its market position without immediate generic competition[1].

Expansion and New Products

Bausch + Lomb has expanded the LUMIFY brand to include new products such as LUMIFY EYE ILLUMINATIONS and LUMIFY Preservative-Free redness reliever eye drops. The Preservative-Free version, approved in April 2024, further enhances the brand's offerings by providing an option for patients who prefer or require preservative-free formulations[1].

Key Takeaways

  • Clinical Trials: Ongoing phase 4 trials are evaluating LUMIFY's efficacy in glaucoma patients, while previous trials have established its safety and efficacy in treating ocular redness.
  • Market Performance: LUMIFY is a market leader in the eye redness reliever category, with significant market share and strong doctor recommendations.
  • Market Projections: LUMIFY is expected to maintain its market position due to its unique formulation and lack of immediate generic competition.
  • Brand Expansion: The LUMIFY brand continues to expand with new products, including preservative-free options, to cater to a broader range of consumer needs.

FAQs

What is LUMIFY and how does it work?

LUMIFY is an OTC eye drop containing low-dose brimonidine tartrate (0.025%) that reduces ocular redness by making the blood vessels in the eyes smaller. It provides relief for up to eight hours with minimal risk of rebound redness[3].

What are the common side effects of LUMIFY?

Common side effects include minor eye irritation, dry mouth, drowsiness, and mild headaches. However, these side effects are generally mild and temporary[4].

Is LUMIFY available in other countries besides the United States?

Yes, LUMIFY has been approved by Health Canada and is available in Canada. It is expected to be available at major pharmacy retailers in various formats[3].

Can I use LUMIFY if I wear contact lenses?

Yes, but you must remove your contact lenses before using LUMIFY and wait at least 10 minutes before re-inserting them[1].

What is the difference between LUMIFY and its generic version?

The generic version of LUMIFY, developed by Lupin Limited, is a biosimilar that contains the same active ingredient (brimonidine tartrate 0.025%) but is manufactured by a different company. However, it cannot be marketed until all patent or exclusivity issues are resolved[1].

Sources

  1. FDA grants tentative approval for Lupin's Lumify generic eye drops - Glance
  2. Net Present Value Model: Lumify - GlobalData
  3. Bausch + Lomb Receives Health Canada Approval of LUMIFY Redness Reliever Eye Drops - PR Newswire
  4. Lumify for Glaucoma Side Effects - Clinical Trials - WithPower
  5. Nielsen's BASES Names LUMIFY Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List - PR Newswire

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.